Repligen Corporation (RGEN) Clibs to All Time High at $47.67 on Jun, 29

June 29, 2018 - By Joseph March

Repligen Corporation (NASDAQ:RGEN) Corporate Logo

Big Money Sentiment increased to 1.39 in Q1 2018. It has change of 0.13, from 2017Q4’s 1.26. The ratio increased due to Repligen Corporation positioning: 13 sold and 46 reduced. 19 funds bought positions and 63 increased positions. Investors holded 35.19 million in 2017Q4 but now own 35.98 million shares or 2.25% more.
Pinebridge Investments Limited Partnership reported 0.01% in Repligen Corporation (NASDAQ:RGEN). Jefferies Gru Ltd Co invested 0% in Repligen Corporation (NASDAQ:RGEN). Thrivent Fincl For Lutherans accumulated 24,375 shs or 0% of the stock. First Manhattan accumulated 0% or 10,500 shs. Teachers Retirement Sys Of The State Of Kentucky accumulated 10,682 shs. Nicholas Inv Lp reported 84,754 shs stake. D E Shaw & holds 0% of its capital in Repligen Corporation (NASDAQ:RGEN) for 8,280 shs. Oakworth Cap owns 1,500 shs for 0.01% of their capital. Pier Cap holds 213,134 shs. Credit Suisse Ag has 40,643 shs. 1,801 were accumulated by Glenmede Tru Na. Citigroup Incorporated accumulated 3,783 shs or 0% of the stock. Goldman Sachs Gp holds 0% or 313,621 shs. Parametric Port Assocs Ltd Liability reported 44,186 shs. Alliancebernstein Ltd Partnership has invested 0% in Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation registered $13.05 million net activity with 0 insider purchases and 8 selling transactions since January 22, 2018. Hunt Anthony had sold 16,249 shs worth $691,016. 4,696 shs were sold by RYAN THOMAS F JR, worth $169,792 on Thursday, March 8. EDDLEMAN ROY T also sold $5.00 million worth of Repligen Corporation (NASDAQ:RGEN) on Wednesday, May 16. BARTHELEMY NICOLAS sold $1.07 million worth of stock.

By reaching $47.67 share price all time high was [achieved] by Repligen Corporation (NASDAQ:RGEN). Barchart.com announced it. The company has $2.08 billion MC. $124.98M more could be NASDAQ:RGEN valuation at $50.53 share price.

RGEN reached $47.67 during the last trading session after $0.88 change.Currently Repligen Corporation is uptrending after 11.84% change in last June 29, 2017. RGEN has 155,508 shares volume. The stock underperformed the S&P500 by 0.73%.

Repligen Corporation (NASDAQ:RGEN) is expected to reveal earnings on August, 2., according to RTT. Analysts expect change of 5.00 % or $0.01 from previous year’s $0.2 earnings per share compared to current’s $0.19 earnings per share. If the current earnings per share of $0.19 is accurate, RGEN’s profit could be $8.30M. 11.76 % EPS growth is what Wall Street’s predicts after $0.17 reported EPS previous quarter.

A couple more Repligen Corporation (NASDAQ:RGEN) news were released by: Globenewswire.com which released on June 11, 2018 “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …”, also Nasdaq.com on June 27, 2018 released “Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity …”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading” on June 27, 2018. Nasdaq.com has article titled “Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand”.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The company has $2.08 billion market cap. It makes various forms of Protein A, a critical component used to purify antibody drugs.66.22 is the P/E ratio. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: